Skip to main content
SpringerLink
Log in

Mantle Cell Lymphoma: Therapeutics and Management

  • Chapter
  • First Online:
Follicular Lymphoma and Mantle Cell Lymphoma

Part of the book series: Molecular and Translational Medicine ((MOLEMED))

  • 445 Accesses

Abstract

Over the past decade, mantle cell lymphoma (MCL), a rare subtype of non-Hodgkin lymphoma, has undergone significant transformation in risk stratification and treatment options available to patients. Frontline management now allows for several approaches to optimize patient responses in both younger and elderly patients. In addition to standard chemotherapy options, targeted therapies improve patient outcomes in relapsed and refractory disease. In this paper we examine the landscape of current treatment modalities for patients with MCL.

A.V.D. is a Leukemia and Lymphoma Society Scholar in Clinical Research (#2319-19)

A.V.D. has received consulting fees from AstraZeneca, Verastem Oncology, Gilead Sciences, Genentech, TG Therapeutics, Beigene, Celgene, Janssen, Curis, Seattle Genetics, and Pharmacyclics over the past 12 months. A.V.D. has ongoing research funding from AstraZeneca, Takeda Oncology, Gilead Sciences, Bayer Oncology, Genentech, Aptose Biosciences, Verastem Oncology, MEI, and Bristol-Myers Squibb.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Vose JM. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2017;92(8):806–13. https://doi.org/10.1002/ajh.24797.

    Article  CAS  PubMed  Google Scholar 

  2. Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA, et al. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol. 2010;150(2):200–8. https://doi.org/10.1111/j.1365-2141.2010.08228.x.

    Article  CAS  PubMed  Google Scholar 

  3. Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton’s tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17(1):57. https://doi.org/10.1186/s12943-018-0779-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Stephens DM, Spurgeon SE. Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion. Ther Adv Hematol. 2015;6(5):242–52. https://doi.org/10.1177/2040620715592569.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Martin P, Chadburn A, Christos P, Weil K, Furman RR, Ruan J, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009;27(8):1209–13. https://doi.org/10.1200/JCO.2008.19.6121.

    Article  PubMed  Google Scholar 

  6. Calzada O, Switchenko JM, Maly JJ, Blum KA, Grover N, Mathews S, et al. Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma. Leuk Lymphoma. 2018;59(12):2862–70. https://doi.org/10.1080/10428194.2018.1455973.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Puente XS, Jares P, Campo E. Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions. Blood. 2018;131(21):2283–96. https://doi.org/10.1182/blood-2017-10-764373.

    Article  CAS  PubMed  Google Scholar 

  8. Clot G, Jares P, Gine E, Navarro A, Royo C, Pinyol M, et al. A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. Blood. 2018;132(4):413–22. https://doi.org/10.1182/blood-2018-03-838136.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Fakhri B, Kahl B. Current and emerging treatment options for mantle cell lymphoma. Ther Adv Hematol. 2017;8(8):223–34. https://doi.org/10.1177/2040620717719616.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Dabaja BS, Zelenetz AD, Ng AK, Tsang RW, Qi S, Allen PK, et al. Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG). Ann Oncol. 2017;28(9):2185–90. https://doi.org/10.1093/annonc/mdx334.

    Article  CAS  PubMed  Google Scholar 

  11. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558–65. https://doi.org/10.1182/blood-2007-06-095331.

    Article  CAS  PubMed  Google Scholar 

  12. Hoster E, Rosenwald A, Berger F, Bernd HW, Hartmann S, Loddenkemper C, et al. Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European mantle cell lymphoma network. J Clin Oncol. 2016;34(12):1386–94. https://doi.org/10.1200/jco.2015.63.8387.

    Article  CAS  PubMed  Google Scholar 

  13. Lenz G, Dreyling M, Hoster E, Wormann B, Duhrsen U, Metzner B, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005;23(9):1984–92. https://doi.org/10.1200/JCO.2005.08.133.

    Article  CAS  PubMed  Google Scholar 

  14. Schulz H, Bohlius JF, Trelle S, Skoetz N, Reiser M, Kober T, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007;99(9):706–14. https://doi.org/10.1093/jnci/djk152.

    Article  CAS  PubMed  Google Scholar 

  15. Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008;112(7):2687. https://doi.org/10.1182/blood-2008-03-147025.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Eskelund CW, Kolstad A, Jerkeman M, Raty R, Laurell A, Eloranta S, et al. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016;175(3):410–8. https://doi.org/10.1111/bjh.14241.

    Article  CAS  PubMed  Google Scholar 

  17. Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol. 2009;27(36):6101–8. https://doi.org/10.1200/JCO.2009.22.2554.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388(10044):565–75. https://doi.org/10.1016/s0140-6736(16)00739-x.

    Article  CAS  PubMed  Google Scholar 

  19. Fenske TS, Zhang MJ, Carreras J, Ayala E, Burns LJ, Cashen A, et al. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. J Clin Oncol. 2014;32(4):273–81. https://doi.org/10.1200/jco.2013.49.2454.

    Article  PubMed  Google Scholar 

  20. Armand P, Redd R, Bsat J, Mayuram S, Giardino A, Fisher DC, et al. A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma. Br J Haematol. 2016;173(1):89–95. https://doi.org/10.1111/bjh.13929.

    Article  CAS  PubMed  Google Scholar 

  21. Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005;23(28):7013–23. https://doi.org/10.1200/jco.2005.01.1825.

    Article  CAS  PubMed  Google Scholar 

  22. Bernstein SH, Epner E, Unger JM, Leblanc M, Cebula E, Burack R, et al. A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. Ann Oncol. 2013;24(6):1587–93. https://doi.org/10.1093/annonc/mdt070.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377(13):1250–60. https://doi.org/10.1056/NEJMoa1701769.

    Article  PubMed  Google Scholar 

  24. Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grunhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–10. https://doi.org/10.1016/S0140-6736(12)61763-2.

    Article  CAS  Google Scholar 

  25. Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944–52. https://doi.org/10.1182/blood-2013-11-531327.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Visco C, Castegnaro S, Chieregato K, Bernardi M, Albiero E, Zanon C, et al. The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines. Blood Cells Mol Dis. 2012;48(1):68–75. https://doi.org/10.1016/j.bcmd.2011.09.007.

    Article  CAS  PubMed  Google Scholar 

  27. Visco C, Finotto S, Zambello R, Paolini R, Menin A, Zanotti R, et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol. 2013;31(11):1442–9. https://doi.org/10.1200/JCO.2012.45.9842.

    Article  CAS  PubMed  Google Scholar 

  28. Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015;372(10):944–53. https://doi.org/10.1056/NEJMoa1412096.

    Article  CAS  PubMed  Google Scholar 

  29. Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012;367(6):520–31. https://doi.org/10.1056/NEJMoa1200920.

    Article  CAS  PubMed  Google Scholar 

  30. Rummel MJ, Knauf W, Goerner M, Soeling U, Lange E, Hertenstein B, et al. Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: first results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial). J Clin Oncol. 2016;34(15_suppl):7503. https://doi.org/10.1200/JCO.2016.34.15_suppl.7503.

    Article  Google Scholar 

  31. Maddocks K. Update on mantle cell lymphoma. Blood. 2018;132(16):1647–56. https://doi.org/10.1182/blood-2018-03-791392.

    Article  CAS  PubMed  Google Scholar 

  32. Goy A, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol. 2009;20(3):520–5. https://doi.org/10.1093/annonc/mdn656.

    Article  CAS  PubMed  Google Scholar 

  33. Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, et al. Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27(23):3822–9. https://doi.org/10.1200/JCO.2008.20.7977.

    Article  CAS  PubMed  Google Scholar 

  34. Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol. 2012;13(7):716–23. https://doi.org/10.1016/S1470-2045(12)70200-0.

    Article  CAS  PubMed  Google Scholar 

  35. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–16. https://doi.org/10.1056/NEJMoa1306220.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126(6):739–45. https://doi.org/10.1182/blood-2015-03-635326.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, et al. Long-term follow-up of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma. Blood. 2018;132(Suppl 1):2876. https://doi.org/10.1182/blood-2018-99-110327.

    Article  Google Scholar 

  38. Brown JR. How I treat CLL patients with ibrutinib. Blood. 2018;131(4):379–86. https://doi.org/10.1182/blood-2017-08-764712.

    Article  CAS  PubMed  Google Scholar 

  39. Brown JR, Moslehi J, O’Brien S, Ghia P, Hillmen P, Cymbalista F, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017;102(10):1796–805. https://doi.org/10.3324/haematol.2017.171041.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Wiczer TE, Levine LB, Brumbaugh J, Coggins J, Zhao Q, Ruppert AS, et al. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. Blood Adv. 2017;1(20):1739–48. https://doi.org/10.1182/bloodadvances.2017009720.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Shatzel JJ, Olson SR, Tao DL, McCarty OJ, Danilov AV, DeLoughery TG. Ibrutinib-associated bleeding: pathogenesis, management, and risk reduction strategies. J Thromb Haemost. 2017. https://doi.org/10.1111/jth.13651.

  42. Awan FT, Schuh A, Brown JR, Furman RR, Pagel JM, Hillmen P, et al. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv. 2019;3(9):1553–62. https://doi.org/10.1182/bloodadvances.2018030007.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Byrd JC, Owen R, O’Brien SM, Brown JR, Hillmen P, Bitman B, et al. Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in hematologic malignancies. Blood. 2017;130(Suppl 1):4326.

    Google Scholar 

  44. Gordon MJ, Churnetski M, Alqahtani H, Rivera X, Kittai A, Amrock SM, et al. Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib. Cancer. 2018;124(15):3192–200. https://doi.org/10.1002/cncr.31554.

    Article  CAS  PubMed  Google Scholar 

  45. Tarantelli C, Zhang L, Curti E, Gaudio E, Spriano F, Priebe V, et al. The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents. Haematologica. 2019;104(7):e307–e9. https://doi.org/10.3324/haematol.2018.214759.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Walter HS, Rule SA, Dyer MJ, Karlin L, Jones C, Cazin B, et al. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood. 2016;127(4):411–9. https://doi.org/10.1182/blood-2015-08-664086.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Cheah CY, Chihara D, Romaguera JE, Fowler NH, Seymour JF, Hagemeister FB, et al. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015;26(6):1175–9. https://doi.org/10.1093/annonc/mdv111.

    Article  CAS  PubMed  Google Scholar 

  48. Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127(12):1559–63. https://doi.org/10.1182/blood-2015-10-673145.

    Article  CAS  PubMed  Google Scholar 

  49. Jain P, Keating M, Wierda W, Estrov Z, Ferrajoli A, Jain N, et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015;125(13):2062–7. https://doi.org/10.1182/blood-2014-09-603670.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 2015;1(1):80–7. https://doi.org/10.1001/jamaoncol.2014.218.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922–6. https://doi.org/10.1038/nm.3884.

    Article  CAS  PubMed  Google Scholar 

  52. Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014. https://doi.org/10.1056/NEJMoa1400029.

  53. Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A, et al. BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol. 2017;35(13):1437–43. https://doi.org/10.1200/JCO.2016.70.2282.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Chiron D, Di Liberto M, Martin P, Huang X, Sharman J, Blecua P, et al. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov. 2014;4(9):1022–35. https://doi.org/10.1158/2159-8290.CD-14-0098.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Kahl BS, Spurgeon SE, Furman RR, Flinn IW, Coutre SE, Brown JR, et al. A phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood. 2014;123(22):3398–405. https://doi.org/10.1182/blood-2013-11-537555.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Iyengar S, Clear A, Bodor C, Maharaj L, Lee A, Calaminici M, et al. P110alpha-mediated constitutive PI3K signaling limits the efficacy of p110delta-selective inhibition in mantle cell lymphoma, particularly with multiple relapse. Blood. 2013;121(12):2274–84. https://doi.org/10.1182/blood-2012-10-460832.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Flinn IW, Miller CB, Ardeshna KM, Tetreault S, Assouline SE, Mayer J, et al. DYNAMO: a phase II study of Duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. J Clin Oncol. 2019;37(11):912–22. https://doi.org/10.1200/JCO.18.00915.

    Article  CAS  PubMed  Google Scholar 

  58. Dreyling M, Santoro A, Mollica L, Leppa S, Follows GA, Lenz G, et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol. 2017;35(35):3898–905. https://doi.org/10.1200/JCO.2017.75.4648.

    Article  CAS  PubMed  Google Scholar 

  59. Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225–36. https://doi.org/10.1056/NEJMoa1815281.

    Article  CAS  PubMed  Google Scholar 

  60. Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D’Rozario J, Assouline S, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107–20. https://doi.org/10.1056/NEJMoa1713976.

    Article  CAS  PubMed  Google Scholar 

  61. Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;35(8):826–33. https://doi.org/10.1200/JCO.2016.70.4320.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Eyre TA, Walter HS, Iyengar S, Follows G, Cross M, Fox CP, et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy. Haematologica. 2018. https://doi.org/10.3324/haematol.2018.198812.

  63. Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med. 2018;378(13):1211–23. https://doi.org/10.1056/NEJMoa1715519.

    Article  CAS  PubMed  Google Scholar 

  64. Blombery P, Anderson MA, Gong JN, Thijssen R, Birkinshaw RW, Thompson ER, et al. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov. 2019;9(3):342–53. https://doi.org/10.1158/2159-8290.CD-18-1119.

    Article  CAS  PubMed  Google Scholar 

  65. Agarwal R, Chan YC, Tam CS, Hunter T, Vassiliadis D, Teh CE, et al. Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. Nat Med. 2019;25(1):119–29. https://doi.org/10.1038/s41591-018-0243-z.

    Article  CAS  PubMed  Google Scholar 

  66. Bojarczuk K, Sasi BK, Gobessi S, Innocenti I, Pozzato G, Laurenti L, et al. BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199. Blood. 2016;127(25):3192–201. https://doi.org/10.1182/blood-2015-10-675009.

    Article  CAS  PubMed  Google Scholar 

  67. Thijssen R, Slinger E, Weller K, Geest CR, Beaumont T, van Oers MH, et al. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. Haematologica. 2015;100(8):e302–6. https://doi.org/10.3324/haematol.2015.124560.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Tromp JM, Geest CR, Breij EC, Elias JA, van Laar J, Luijks DM, et al. Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia. Clin Cancer Res. 2012;18(2):487–98. https://doi.org/10.1158/1078-0432.CCR-11-1440.

    Article  CAS  PubMed  Google Scholar 

  69. Gill S, Herbert KE, Prince HM, Wolf MM, Wirth A, Ryan G, et al. Mantle cell lymphoma with central nervous system involvement: frequency and clinical features. Br J Haematol. 2009;147(1):83–8. https://doi.org/10.1111/j.1365-2141.2009.07835.x.

    Article  PubMed  Google Scholar 

  70. Cheah CY, George A, Gine E, Chiappella A, Kluin-Nelemans HC, Jurczak W, et al. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. Ann Oncol. 2013;24(8):2119–23. https://doi.org/10.1093/annonc/mdt139.

    Article  CAS  PubMed  Google Scholar 

  71. Bernard S, Goldwirt L, Amorim S, Brice P, Briere J, de Kerviler E, et al. Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse. Blood. 2015;126(14):1695–8. https://doi.org/10.1182/blood-2015-05-647834.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen LB, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130(17):1903–10. https://doi.org/10.1182/blood-2017-04-779736.

    Article  CAS  PubMed  Google Scholar 

  73. Greenwell IB, Staton AD, Lee MJ, Switchenko JM, Saxe DF, Maly JJ, et al. Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. Cancer. 2018;124(11):2306–15. https://doi.org/10.1002/cncr.31328.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Advocate Lutheran General Hospital, Park Ridge, IL, USA

    Edward A. Nabrinsky

  2. City of Hope National Medical Center, Duarte, CA, USA

    Alexey V. Danilov

Authors
  1. Edward A. Nabrinsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexey V. Danilov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexey V. Danilov .

Editor information

Editors and Affiliations

  1. Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, 1 Medical Center Drive, Lebanon, NH, USA

    Prabhjot Kaur

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Nabrinsky, E.A., Danilov, A.V. (2020). Mantle Cell Lymphoma: Therapeutics and Management. In: Kaur, P. (eds) Follicular Lymphoma and Mantle Cell Lymphoma. Molecular and Translational Medicine. Humana, Cham. https://doi.org/10.1007/978-3-030-49741-5_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-49741-5_6

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-49740-8

  • Online ISBN: 978-3-030-49741-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation